JP2024533756A5 - - Google Patents

Info

Publication number
JP2024533756A5
JP2024533756A5 JP2024519064A JP2024519064A JP2024533756A5 JP 2024533756 A5 JP2024533756 A5 JP 2024533756A5 JP 2024519064 A JP2024519064 A JP 2024519064A JP 2024519064 A JP2024519064 A JP 2024519064A JP 2024533756 A5 JP2024533756 A5 JP 2024533756A5
Authority
JP
Japan
Prior art keywords
atgepant
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077061 external-priority patent/WO2023049920A1/en
Publication of JP2024533756A publication Critical patent/JP2024533756A/ja
Publication of JP2024533756A5 publication Critical patent/JP2024533756A5/ja
Pending legal-status Critical Current

Links

JP2024519064A 2021-09-27 2022-09-27 アトゲパントを含む片頭痛の併用療法 Pending JP2024533756A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163261731P 2021-09-27 2021-09-27
US63/261,731 2021-09-27
US202163261782P 2021-09-28 2021-09-28
US202163261783P 2021-09-28 2021-09-28
US63/261,783 2021-09-28
US63/261,782 2021-09-28
US202263336843P 2022-04-29 2022-04-29
US63/336,843 2022-04-29
US202263395134P 2022-08-04 2022-08-04
US63/395,134 2022-08-04
PCT/US2022/077061 WO2023049920A1 (en) 2021-09-27 2022-09-27 Combination comprising atogepant for treating migraine

Publications (2)

Publication Number Publication Date
JP2024533756A JP2024533756A (ja) 2024-09-12
JP2024533756A5 true JP2024533756A5 (enExample) 2025-10-03

Family

ID=83899967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519064A Pending JP2024533756A (ja) 2021-09-27 2022-09-27 アトゲパントを含む片頭痛の併用療法

Country Status (7)

Country Link
US (6) US12350259B2 (enExample)
EP (1) EP4408418A1 (enExample)
JP (1) JP2024533756A (enExample)
AU (1) AU2022353124A1 (enExample)
CA (1) CA3234080A1 (enExample)
MX (1) MX2024003952A (enExample)
WO (1) WO2023049920A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CA2479672A1 (en) 2002-03-18 2003-10-02 Roger K. Cady Preemptive prophylaxis of migraine
DE10228326A1 (de) * 2002-06-25 2004-01-22 Heribert Dr.med. Bohlen Verwendung von Macrolid- und/oder Tetracyclin-Verbindungen und/oder Gyrasehemmer enthaltenden Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2543458A1 (en) 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US8003792B2 (en) 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
DE102004063755A1 (de) 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CN101378731B (zh) 2006-02-09 2014-03-05 默沙东公司 Cetp抑制剂的聚合物制剂
WO2007133491A1 (en) 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
CA2689217C (en) 2007-06-05 2016-02-16 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
EP2225237A2 (de) 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
JP2011511792A (ja) 2008-02-05 2011-04-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストのプロドラッグ
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US20150023888A1 (en) 2008-09-05 2015-01-22 Map Pharmaceuticals, Inc. Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012064911A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012087777A1 (en) 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide cgrp receptor antagonists
EP2654423B1 (en) 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012129013A1 (en) 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
EP2753640B1 (en) 2011-09-08 2016-03-09 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
WO2013138418A2 (en) 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Process for making cgrp receptor antagonists
WO2013138413A1 (en) 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
WO2013162769A1 (en) 2012-04-25 2013-10-31 Centric Research Institute Sensitization composition and method of use
US9227972B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
WO2013169563A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2846799B1 (en) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
WO2015038736A2 (en) 2013-09-16 2015-03-19 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
US20240180883A1 (en) 2020-12-22 2024-06-06 Allergan Pharmaceuticals International Limited Treatment of migraine
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
EP3102188A4 (en) 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
CN106456662A (zh) 2014-02-24 2017-02-22 奥利金制药公司 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
CN107427493A (zh) 2015-01-23 2017-12-01 格吕伦塔尔有限公司 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol
JP2018532728A (ja) 2015-09-24 2018-11-08 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー （持続性）外傷後頭痛の予防、治療および低減
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
JP7195262B2 (ja) 2017-03-02 2022-12-23 ベス イスラエル デアコネス メディカル センター インコーポレイティッド カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
US20200353088A1 (en) 2017-11-06 2020-11-12 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
US20190374520A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TW202019459A (zh) 2018-07-05 2020-06-01 愛爾蘭商歐樂根製藥國際有限公司 Cgrp拮抗劑及梭菌衍生物之組合療法
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
KR20210116560A (ko) 2019-01-20 2021-09-27 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 편두통 돌발을 치료하기 위한 cgrp 길항제
US20200383983A1 (en) 2019-04-18 2020-12-10 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
WO2021005494A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders
EP4034156A4 (en) 2019-09-25 2024-01-24 Allergan Pharmaceuticals International Limited COMBINATION THERAPY WITH CGRP ANTAGONISTS
BR112022008118A2 (pt) * 2019-10-31 2022-07-19 Scherer Technologies Llc R P Cápsula de supositório
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
CA3244873A1 (en) 2022-03-09 2023-09-14 Allergan Pharmaceuticals International Limited Preventive treatment for migraines
US20260130901A1 (en) 2022-10-11 2026-05-14 Allergan Pharmaceuticals International Limited Cgrp receptor antagonist for the treatment of migraine

Similar Documents

Publication Publication Date Title
JP2023041862A5 (enExample)
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP5767122B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
JP2002541097A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
JP2017132791A (ja) 組み合わせ組成物
JP2020504129A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法
JP2020522560A5 (enExample)
JP2020523334A5 (enExample)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
KR100404303B1 (ko) 올티프라즈의 간섬유화 및 간경화 진행의 예방 및치료제로서의 용도 및 올티프라즈를 주성분으로 함유하는제약 조성물
JP2020519576A5 (enExample)
JP2004525143A5 (enExample)
JP2016505050A5 (enExample)
CN1976723B (zh) 制备治疗或预防感染性疾病的药物的用途
JP2025511402A5 (enExample)
JP2025511401A5 (enExample)
JP2022177119A5 (enExample)
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
CN107773559B (zh) 吲哚啉酮类化合物在制备预防治疗肺纤维化的药物中的应用
JP2025522146A5 (enExample)
CN103635194A (zh) 用于治疗早泄的药物组合物以及用于治疗早泄的方法
US20190381034A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
KR20070074576A (ko) 사구체 질환 치료제